Intuitive Surgical, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- David J. Rosa
- Full Time Employees
- 15,638
- Sector
- Healthcare
- Industry
- Medical - Devices
- Address
- 1020 Kifer Road Sunnyvale CA United States of America 94086-5304
- IPO Date
- Jun 16, 2000
- CIK
- 0001035267
- Website
- intuitive.com
- Similar Companies
- Business
- Intuitive Surgical, Inc. develops, manufactures, and markets advanced robotic-assisted surgical systems designed to enhance the quality and access to minimally invasive care globally. Its core products include the da Vinci Surgical System, which enables surgeons to perform a wide range of complex surgical procedures across specialties such as general surgery, urology, gynecology, cardiothoracic, and head and neck surgery using minimally invasive techniques. The company also offers the Ion Endoluminal System, a robotic platform for diagnostic endoluminal procedures enabling minimally invasive lung biopsies through advanced imaging and navigation technology. Intuitive’s product suite includes stapling, energy, and core instrumentation compatible with its multi-port da Vinci systems, alongside progressive learning pathways that facilitate clinical adoption, and a comprehensive infrastructure of service and support including installation, maintenance, technical support, proactive system health monitoring, and integrated digital capabilities that provide hospitals with data-driven insights to optimize surgical performance. Founded in 1995 and headquartered in Sunnyvale, California, Intuitive Surgical operates globally, supporting hospitals and surgical teams across over 60 countries. In the last 1-2 years, the company has advanced the commercial launch of its da Vinci 5 Surgical System, receiving regulatory clearances from the US FDA and CE mark in 2024, with 2025 focused on scaling the adoption of this platform through enhanced hardware and software upgrades featuring increased computing power and digital capabilities. Intuitive reported significant growth in system placements and procedure volumes, with a 14% year-over-year increase in installed base and 17% procedural growth as of mid-2025. Strategic priorities include expanding its robotic surgery ecosystem, reinforcing its recurring revenue model—which accounted for 84% of revenue in 2024—and furthering its Quintuple Aim framework aimed at improving patient outcomes, care team experience, access to care, and lowering total costs. Additionally, leadership transitioned in mid-2025 with President Dave Rosa promoted to CEO, signaling a new phase of growth and innovation focus. Despite rising competition in the robotic surgery field, Intuitive remains a dominant market leader through continuous technological innovation and strategic expansion. This comprehensive offering positions Intuitive Surgical as a pioneer and global leader in robotic-assisted, minimally invasive surgical technology, serving healthcare providers with products, services, and digital innovations that collectively enhance surgical precision, patient recovery, and overall healthcare system efficiency.
Intuitive Surgical, Inc. (ISRG) is Attracting Investor Attention: Here is What You Should Know
Intuitive Surgical, Inc. (ISRG) Rises As Market Takes a Dip: Key Facts
Intuitive Surgical (ISRG) Upgraded to Buy: Here's Why
Will ISRG's Cost Leverage Aid Margins Amid Tariff & Input Inflation?
3 Stocks I'm Not Selling No Matter What the Market Does for the Next 20 Years
Can Medtronic Finally Challenge Intuitive Surgical's Robotic Surgical Systems Dominance?
Bargain Hunters: These 3 Growth Stocks Recently Hit New 52-Week Lows
Intuitive Surgical Stock Has Been Hit Hard in 2026. Is It Finally Time to Buy?
Intuitive Surgical: A Strong Contender in the Healthcare Sector
Why the Market Dipped But Intuitive Surgical, Inc. (ISRG) Gained Today
ISRG Falls 11% in a Month: Is a Reversal on the Cards for the Stock?
Can ISRG's Digital Roadmap Unlock the Next Phase of Robotic Surgery?
ISRG DCF Analysis: Intrinsic Value $196 vs Price $412
3 Beaten-Down Stocks to Buy and Hold Forever
Intuitive Surgical, Inc. (ISRG) Is a Trending Stock: Facts to Know Before Betting on It
A Rare Buying Opportunity May Be Here With This Top Stock
Wall Street Thinks Intuitive Surgical Stock Can Soar Over 30%. Here's Why Analysts are Right.
5 Stocks With Real Revenue From Physical AI Today (Not 2030 Promises)
Intuitive Announces New Chief Commercial and Marketing Officer Taylor Patton
Here is Why Growth Investors Should Buy Intuitive Surgical (ISRG) Now